Thoma Bryan, Straube Eberhard, Scholz Holger C, Al Dahouk Sascha, Zöller Lothar, Pfeffer Martin, Neubauer Heinrich, Tomaso Herbert
Bundeswehr Institute of Microbiology, Munich, Germany.
Int J Med Microbiol. 2009 Mar;299(3):209-20. doi: 10.1016/j.ijmm.2008.06.009. Epub 2008 Aug 27.
Ochrobactrum (O.) anthropi is an opportunistic emerging pathogen closely related to the genus Brucella. Identification and differentiation from brucellae and other Ochrobactrum spp. using routine biochemical test systems is not reliable due to the high phenotypic similarity. In this study, antibiotic susceptibilities of 103 Ochrobactrum isolates were determined using Etest for 19 clinically relevant antimicrobial agents. Ochrobactrum strains were highly resistant to beta-lactam antibiotics, susceptible to ciprofloxacin, and 97.1% were susceptible to trimethoprim/sulfamethoxazole. It was also demonstrated that biochemical reaction profiles of the API and BD Phoenix 100 systems for identifying Ochrobactrum isolates can only be used on the genus level. Our in vitro data suggest that combinations of antimicrobial agents including ciprofloxacin and/or trimethoprim/sulfamethoxazole may be useful for empirical treatment of Ochrobactrum infections.
嗜水气单胞菌(Ochrobactrum)是人畜共患的机会致病菌,与布鲁氏菌属密切相关。由于表型高度相似,使用常规生化检测系统鉴定嗜水气单胞菌并与布鲁氏菌及其他嗜水气单胞菌属进行区分并不可靠。在本研究中,使用Etest法测定了103株嗜水气单胞菌对19种临床相关抗菌药物的敏感性。嗜水气单胞菌菌株对β-内酰胺类抗生素高度耐药,对环丙沙星敏感,97.1%的菌株对甲氧苄啶/磺胺甲恶唑敏感。研究还表明,用于鉴定嗜水气单胞菌菌株的API和BD Phoenix 100系统的生化反应谱仅可用于属水平的鉴定。我们的体外数据表明,包括环丙沙星和/或甲氧苄啶/磺胺甲恶唑在内的抗菌药物组合可能有助于经验性治疗嗜水气单胞菌感染。